METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
Clinical trials for METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Long-Lasting injection tested for Tough-to-Treat prostate cancer
Disease control Recruiting nowThis study is testing a new long-acting injection called PRL-02 for men with advanced prostate cancer that has returned or stopped responding to prior treatment. The main goals are to find a safe and tolerable dose and to see how well the body handles the drug. Men in the study w…
Matched conditions: METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
Phase: PHASE1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Apr 01, 2026 21:56 UTC
-
Major trial aims to delay prostate cancer progression in 1,800 men
Disease control Recruiting nowThis large, late-stage study is testing whether adding an experimental drug called saruparib to standard hormone therapy helps men with metastatic prostate cancer that still responds to hormone treatment. About 1,800 participants will be randomly assigned to receive either the ne…
Matched conditions: METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC